Efficacy and Safety of First Line Vincristine with Doxorubicin, Bleomycin and Dacarbazine (ABOD) for Hodgkin’s Lymphoma: a Single Institute Experience

Abstract

<b>Background:</b> ABVD (doxorubicin, bleomycin, vinblastine (Vb) and dacarbazine) is the standard regimen inHodgkin’s lymphoma (HL).Vincristine (O) is a mitotic spindle agent like Vb. We aimed to evaluate the efficacyand safety of O as a part of ABOD in HL. Materials and <br/><b>Methods</b>: Patients who had ABOD were enrolled. StageI-II HL were evaluated for unfavorable risk factors according to NCCN. National Cancer Institute CommonToxicity Criteria was used for toxicity. <br/><b>Results</b>: Seventy-nine HL patients in our center between 2003 and 2007were evaluated retrospectively. Median follow-up was 54 months. Most of the patients were male in their thirddecade. Median ABOD cycles were 6 (2-8). Primary refractory disease rate was 17.7% whereas it was 5.1% forearly relapse and 5.1% for late relapse disease. Response rates were as 82.3% for complete response, 11.4%for partial response, 5.1% for stable disease and 1.3% for progressive disease. Half of relapsed patients hadautologous stem cell transplantation. Estimated 5-year failure-free survival was 71% and significantly longerin early stage patients without risk factors, bulky disease or radiotherapy (RT) (p=0.05, p<0.0001, p=0.02;respectively). Estimated 5-year overall survival was 74% and significantly longer in those who had no RT(p=0.001). Dose modification rate was 5.1% and chemotherapy delay rate was 19%. There were no toxicityrelateddeaths. <br/><b>Conclusions</b>: ABOD seems to be effective with managable toxicity in HL, even in those with poorprognostic factors.